COMMUNIQUÉS West-GlobeNewswire

ProMIS Neurosciences Presents at AAIC 2017 Data from Alzheimer's Disease Program
19/07/2017
Company Focused on Development of Antibodies that Selectively Target Toxic, Prion-Like Forms of Amyloid beta ProMIS Issues White Paper from AAIC Presentations Outlining Role of Toxic Misfolded Forms of Amyloid beta and [...]
Orion Group Half-Year Financial Report January-June 2017
19/07/2017
ORION CORPORATION HALF-YEAR FINANCIAL REPORT JANUARY-JUNE 2017 19 JULY 2017 AT 13.15 EEST Orion Group Half-Year Financial Report January-June 2017 Orion's net sales in January-June 2017 totalled EUR 552 million (EUR 535 [...]
Orion Corporation's financial reporting and Annual General Meeting in 2018
19/07/2017
ORION CORPORATION STOCK EXCHANGE RELEASE 19 JULY 2017 at 11.00 A.M. EEST Orion Corporation's financial reporting and Annual General Meeting in 2018 Orion Corporation will publish its Financial Statement Release 2017 on [...]
RECORDATI: THE EUROPEAN COMMISSION APPROVES REAGILA® (CARIPRAZINE) FOR THE TREATMENT OF SCHIZOPHRENIA
19/07/2017
Milan, 19 July 2017 - Recordati announces that Gedeon Richter Plc. was granted marketing authorization from the European Commission for Reagila® (cariprazine), a novel antipsychotic for the treatment of schizophrenia in [...]
MPI: OV to evaluate the potential of in-licensing a small molecule compound for development in cancer from a major Pharmaceutical company
19/07/2017
Hoersholm, Denmark, July 19, 2017 - Oncology Venture AB (OV:ST) and Novartis Pharma AG (Basel, Switzerland) have entered into an agreement providing Oncology Venture with an option right to execute an exclusive license [...]
NEOVACS obtient une nouvelle « Investigational New Drug (IND) » de la FDA dans la dermatomyosite aux Etats-Unis
19/07/2017
COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE Néovacs annonce avoir obtenu une nouvelle « Investigational New Drug ( IND ) » de la FDA pour élargir son programme de développement clinique avec l' [...]
Neovacs Announces FDA Acceptance of a New IND to Expand in U.S. IFNalpha Kinoid Clinical Development Program in Dermatomyositis
19/07/2017
PRESS RELEASE · PRESS RELEASE · PRESS RELEASE Neovacs Announces FDA Acceptance of a New IND to Expand in U.S. IFNalpha Kinoid Clinical Development Program in Dermatomyositis This is the second clinical trial approved by [...]
ELSALYS BIOTECH et le prestigieux institut allemand de recherche sur le cancer DKFZ initient le développement d'ELB021 dans la leucémie à cellules B avec le soutien de l'Union Européenne
18/07/2017
ELSALYS BIOTECH et le prestigieux institut allemand de recherche sur le cancer DKFZ initient le développement d'ELB021 dans la leucémie à cellules B avec le soutien de l'Union Européenne ELB021 est un anticorps [...]
ELSALYS BIOTECH and the prestigious German cancer research institute DKFZ initiate the development of ELB021 in B-Cell leukemia with the support of EU
18/07/2017
ELSALYS BIOTECH and the prestigious German cancer research institute DKFZ initiate the development of ELB021 in B-Cell leukemia with the support of EU ELB021 is a proprietary first-in-class monoclonal antibody targeting [...]
PHARMAGEST INTERACTIVE : acquisition majeure sur le marché de l'informatique hospitalière
18/07/2017
Villers-lès-Nancy, le 18 Juillet 2017 - 19h00 (CET) COMMUNIQUE DE PRESSE SYSTEME D'INFORMATION DE SANTE A L'HOPITAL ACQUISITION MAJEURE MALTA INFORMATIQUE, filiale du Groupe PHARMAGEST ( Euronext Paris #FR 0012882389 - [...]
SPINEWAY : Croissance confirmée sur le 1er semestre 2017 Chiffre d'affaires de 6M€ (+ 146%)
18/07/2017
Communiqué de presse Ecully, le 18 juillet 2017 Croissance confirmée sur le 1 er semestre 2017 Chiffre d'affaires de 6M€ (+ 146%) En Milliers d'euros 2016 2017* 1 er trimestre 1 109 3 110 2 ème trimestre 1 330 2 901 CA [...]
SPINEWAY : Confirmed growth Revenue for the first half of 2017: €6M (+146%)
18/07/2017
Press release Ecully, 18 July 2017 Confirmed growth Revenue for the first half of 2017: €6M (+146%) In thousands of euros 2016 2017* 1 st quarter 1 109 3 110 2 nd quarter 1 330 2 901 HY 1 revenue 2 439 6 010 * Figures [...]
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlemen...
18/07/2017
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l' [...]
Informations relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du Code de commerce et l'article 223-16 du Règlement général de l'Autorité des Marchés Financ...
18/07/2017
Informations relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du Code de commerce et l'article 223-16 du Règlement général de l'Autorité des Marchés Financiers Sanofi Société [...]
NICOX : Nombre de droits de vote au 17 juillet 2017
18/07/2017
Nicox SA Société anonyme au capital de 25 669 338 euros Siège social : DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 Le 17 juillet 2017, PUBLICATION MENSUELLE DU NOMBRE D' [...]
NICOX : Number of voting rights as of July 17, 2017
18/07/2017
Number Nicox SA Société anonyme with a registered capital of € 25,669,338 Head Office: DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 On July 17, 2017, MONTHLY PUBLICATION OF [...]
Summit Therapeutics plc : Result of AGM
18/07/2017
Summit Therapeutics plc ('Summit' or 'the Company') RESULT OF ANNUAL GENERAL MEETING Oxford, UK, 18 July 2017 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing [...]
FIT Biotech Oy: FIT Biotech Oy's Board of Directors has decided on the issue of Convertible Notes and Warrants
18/07/2017
FIT Biotech Oy Company release July 18, 2017 at 4:00 pm FIT Biotech Oy's Board of Directors has decided on the issue of Convertible Notes and Warrants On September 26, 2016, the Board of Directors of FIT Biotech Oy ( [...]
Shire Expands Broad Monoclonal Antibody Research Platform, Enters License Agreement for Novimmune Bi-specific Antibody
18/07/2017
Shire Expands Broad Monoclonal Antibody Research Platform, Enters License Agreement for Novimmune Bi-specific Antibody Shire obtains worldwide license to pursue development and commercialization of a novel, potentially [...]

Pages